Literature DB >> 8698528

Pulmonary damage by Vibrio vulnificus cytolysin.

J W Park1, S N Ma, E S Song, C H Song, M R Chae, B H Park, R W Rho, S D Park, H R Kim.   

Abstract

Vibrio vulnificus is an estuarine bacterium that causes septicemia and serious wound infection. Cytolysin produced by V. vulnificus has been incriminated as one of the important virulence determinants of bacterial infection. Cytolysin (8 hemolytic units) given intravenously to mice via their tail veins caused severe hemoconcentration and lethality. Cytolysin treatment greatly increased pulmonary wet weight and vascular permeability as measured by (125)I-labeled albumin leakage without affecting those factors of other organs significantly. Blood neutrophils were markedly decreased in number after cytolysin injection, with a concomitant increase in the level of pulmonary myeloperoxidase activity, indicating that cytolysin-induced neutropenia might be due to pulmonary sequestration of neutrophils. By microscopic examination, severe perivascular edema and neutrophil infiltration were evident in lung tissues. These results suggest that increased vascular permeability and neutrophil sequestration in the lungs are important factors in lethal activity by cytolysin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698528      PMCID: PMC174159          DOI: 10.1128/iai.64.7.2873-2876.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

Review 1.  Tissue destruction by neutrophils.

Authors:  S J Weiss
Journal:  N Engl J Med       Date:  1989-02-09       Impact factor: 91.245

Review 2.  Damage to cell membranes by pore-forming bacterial cytolysins.

Authors:  S Bhakdi; J Tranum-Jensen
Journal:  Prog Allergy       Date:  1988

3.  Cytolytic toxins of Vibrio vulnificus and Vibrio damsela.

Authors:  A S Kreger; M H Kothary; L D Gray
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

4.  Production of extracellular enzymes and cytotoxicity by Vibrio vulnificus.

Authors:  J D Oliver; J E Wear; M B Thomas; M Warner; K Linder
Journal:  Diagn Microbiol Infect Dis       Date:  1986-07       Impact factor: 2.803

5.  Perspectives in endothelial cell biology.

Authors:  S M Albelda; M J Karnovsky; A P Fishman
Journal:  J Appl Physiol (1985)       Date:  1987-04

6.  Multiple systems organ failure: I. The basal state.

Authors:  R H McMenamy; R Birkhahn; G Oswald; R Reed; C Rumph; N Vaidyanath; L Yu; F B Cerra; R Sorkness; J R Border
Journal:  J Trauma       Date:  1981-02

7.  Neutrophil-mediated pulmonary vascular injury. Synergistic effect of trace amounts of lipopolysaccharide and neutrophil stimuli on vascular permeability and neutrophil sequestration in the lung.

Authors:  G S Worthen; C Haslett; A J Rees; R S Gumbay; J E Henson; P M Henson
Journal:  Am Rev Respir Dis       Date:  1987-07

8.  Neutrophil-derived oxygen metabolites stimulate thromboxane release, pulmonary artery pressure increases, and weight gains in isolated perfused rat lungs.

Authors:  R J McDonald; E M Berger; J E Repine
Journal:  Am Rev Respir Dis       Date:  1987-04

9.  Mouse skin damage caused by cytolysin from Vibrio vulnificus and by V. vulnificus infection.

Authors:  L D Gray; A S Kreger
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

10.  Staphylococcal alpha toxin promotes blood coagulation via attack on human platelets.

Authors:  S Bhakdi; M Muhly; U Mannhardt; F Hugo; K Klapettek; C Mueller-Eckhardt; L Roka
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

View more
  8 in total

1.  Isolation and characterization of a Vibrio vulnificus mutant deficient in both extracellular metalloprotease and cytolysin.

Authors:  J J Fan; C P Shao; Y C Ho; C K Yu; L I Hor
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

2.  Low density lipoprotein inactivates Vibrio vulnificus cytolysin through the oligomerization of toxin monomer.

Authors:  Kwang-Hyun Park; Haet-Bit Yang; Hyung-Gue Kim; Young-Rae Lee; Hyoun Hur; Jong-Soo Kim; Bon-Sun Koo; Myung-Kwan Han; Jong-Hyun Kim; Young-Ju Jeong; Jong-Suk Kim
Journal:  Med Microbiol Immunol       Date:  2004-11-20       Impact factor: 3.402

3.  Pathogenesis of infection by clinical and environmental strains of Vibrio vulnificus in iron-dextran-treated mice.

Authors:  A M Starks; T R Schoeb; M L Tamplin; S Parveen; T J Doyle; P E Bomeisl; G M Escudero; P A Gulig
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice.

Authors:  Karen E Cerveny; Angelo DePaola; Donna H Duckworth; Paul A Gulig
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

5.  Construction and phenotypic evaluation of a Vibrio vulnificus vvpE mutant for elastolytic protease.

Authors:  K C Jeong; H S Jeong; J H Rhee; S E Lee; S S Chung; A M Starks; G M Escudero; P A Gulig; S H Choi
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

6.  A calcium-calmodulin antagonist blocks experimental Vibrio vulnificus cytolysin-induced lethality in an experimental mouse model.

Authors:  Young-Rae Lee; Kwang-Hyun Park; Zhao-Zhen Lin; Young-Jong Kho; Jin-Woo Park; Hye-Won Rho; Bon-Sun Koo; Hyung-Rho Kim; Eun-Kyung Song; Hong-Nu Yu; Myung-Kwan Han; Seung-Ok Lee; Eun-Chung Jhee; Jong-Suk Kim
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 7.  Increased Vascular Permeability Due to Spread and Invasion of Vibrio vulnificus in the Wound Infection Exacerbates Potentially Fatal Necrotizing Disease.

Authors:  Kohei Yamazaki; Takashige Kashimoto; Takehiro Kado; Kazuki Yoshioka; Shunji Ueno
Journal:  Front Microbiol       Date:  2022-03-08       Impact factor: 5.640

8.  Biomimetic Nanosponges Enable the Detoxification of Vibrio vulnificus Hemolysin.

Authors:  Shuaijun Zou; Qianqian Wang; Peipei Zhang; Bo Wang; Guoyan Liu; Fuhai Zhang; Jie Li; Fan Wang; Beilei Wang; Liming Zhang
Journal:  Int J Mol Sci       Date:  2022-06-19       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.